fasudil has been researched along with Bright Disease in 2 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil treatment significantly improved survival and decreased proteinuria, particularly when treatment was started at 18 weeks." | 1.38 | Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. ( Bhagat, G; Biswas, PS; Gupta, S; Pernis, AB; Song, L; Stirzaker, RA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stirzaker, RA | 1 |
| Biswas, PS | 1 |
| Gupta, S | 1 |
| Song, L | 1 |
| Bhagat, G | 1 |
| Pernis, AB | 1 |
| Hidaka, T | 1 |
| Suzuki, Y | 1 |
| Yamashita, M | 1 |
| Shibata, T | 1 |
| Tanaka, Y | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
2 other studies available for fasudil and Bright Disease
| Article | Year |
|---|---|
Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antigen-Antibody Compl | 2012 |
Amelioration of crescentic glomerulonephritis by RhoA kinase inhibitor, Fasudil, through podocyte protection and prevention of leukocyte migration.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Blood Urea Nitrogen; Cells, | 2008 |